Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.
Breast Cancer Metastatic
DRUG: Apatinib
Progression free survival, Baseline to measured date of progression or death from any cause, evaluated in 24 months since the treatment began
Overall survival, Baseline to measured date of death from any cause, the first day of treatment to death or last survival confirm date,up to 24 months|Disease control rate, Baseline to measured progressive disease, tumor assessment every 6 weeks since the treatment began，up to 24 months|Objective response rate, Baseline to measured stable disease, tumor assessment every 6 weeks since the treatment began，up to 24 months|Side effects, throughout study, evaluated in the 24th month since the treatment began according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.